Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
The Company’s global patent portfolio includes granted patents in the United States, Europe, India, Australia, China and Hong Kong, and numerous pending patents worldwide
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a pioneering AI-driven precision cardiovascular medicine company, today announced that India’s Patent Office has granted a patent to the University of Iowa Research Foundation (“UIRF”) under patent number 484488, titled “A Kit for Determining Methylation Status of a CpG Dinucleotide and a Genotype of a Single Nucleotide Polymorphism.”
The patent was exclusively licensed to the Company from the University of Iowa Research Foundation (UIRF). It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.
Heart Disease in India Begins Earlier in Adults
The burden of heart disease in India is substantial and growing, driven by high prevalence rates, significant risk factors, high mortality, and lack of access to specialty cardiology settings. Particularly concerning is the early onset of cardiovascular disease in Indians compared to their western counterparts; Indians are found to develop cardiovascular disease 10-years earlier and during their prime work years. Based on the age at which many Indians are struck with heart disease, the World Economic Forum and Harvard School of Public Health estimate that India’s economic losses related to cardiovascular disease will exceed $2.5 trillion.
By partnering with Indian business leaders to introduce innovative precision-based cardiovascular diagnostic methods and advanced management insights, the Company can help accelerate preventive health initiatives and improve cardiovascular health outcomes in India. This presents a significant opportunity for Cardio Diagnostics to expand its footprint in the world’s fastest growing nation by population.
Expanding Access to Scalable Heart Disease Solutions in India
Cardio Diagnostics recently entered into a Supply and Distribution Agreement with Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932 with 14 sales and services offices across India. Aimil is a leader in introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India.
“Securing this patent in India is a significant milestone for the company, especially with our ongoing collaboration with Aimil to introduce our solutions in India through Aimil’s extensive healthcare network,” said Meesha Dogan Ph.D., CEO and Co-founder of Cardio Diagnostics. “We’re committed to leading the fight against heart disease globally and are excited for the synergies that lie ahead.”
Marie Kerbeshian, Ph.D., Executive Director of UIRF, said, “University of Iowa remains steadfast in partnering with companies like Cardio Diagnostics that are dedicated to tackling global healthcare challenges such as heart disease. Cardio Diagnostics exemplifies the transformation of cutting-edge research into Precision Medicine solutions with the potential to impact and save lives worldwide.”
The Company’s robust intellectual property portfolio includes granted patents in the United States, Europe, India, China, Australia and Hong Kong, numerous pending patents worldwide, proprietary laboratory assays, proprietary AI-driven Integrated Genetic-Epigenetic Engine, proprietary Risk Intelligence platform (HeartRisk), proprietary AI algorithms of the Epi+Gen CHD and PrecisionCHD clinical tests, and a multitude of other trade secrets. The company remains committed to developing and protecting its innovative technologies that can improve cardiovascular health outcomes for patients globally.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Forms 10-Q for the periods ended March 31, 2023 and September 30, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Contacts
Investors:
Gene Mannheimer
Investor Relations
855-226-9991
investors@cardiodiagnosticsinc.com
Media & Public Relations:
Khullani Abdullahi
855-226-9991
pr@cardiodiagnosticsinc.com
